Sona Nanotech Inc., - CEO, Darren Rowles
CEO, Darren Rowles
Source: The Chronicle Herald
Market Herald logo


Be the first with the news that moves the market
  • Sona Nanotech (CSE:SONA) has recruited scientific advisors to help develop a coronavirus rapid screening test
  • Fiona Marshall and Sandy Morrison will assist in developing and seeking FDA approval for the company’s rapid-response test
  • Sona’s initial laboratory work on the test is progressing well, and is likely to accelerate
  • Sona’s share price is down 12.05 per cent, and is currently trading at $0.73 per share

Sona Nanotech (CSE:SONA) has recruited two scientific advisors, who will assist to develop a coronavirus rapid screening test.

Fiona Marshall, the CEO of AgPlus Diagnostics, will help the Sona team with the scientific considerations of the test development. She will also assist with manufacturing set-up, quality control, and regulatory approval.

Ms Marshall has extensive experience in this area, having previously established a facility for producing lateral flow tests. This included tests for Class 3 deadly pathogens that served US military contracts. 

Ms Marshall also oversaw the development of a rapid-response test development program during the Ebola outbreak of 2013.

Fiona stated that she was familiar with, and happy to join the team Sona has built around the COVID-19 rapid response test.

“I look forward to working with industry leaders like The Native Antigen Company and General Health Electric Health Care Life Sciences. I look forward to working with the highly-sensitive Sona nanoparticles to get this much-needed test to market as quickly as possible,” she added.

President of Quality Systems Atlantic, Sandy Morrison, will assist Sona with its ongoing application for FDA Emergency Use Authorisation. 

Mr Morrison has over 30 years of experience in the medical industry, and is familiar with regulatory affairs. He helped to obtain regulatory approval from Health Canada and the FDA for the first rapid HIV test.

Sona Nanotech CEO, Darren Rowles, commented on the additions to the company, and provided an update on the test development.

“We are very happy to welcome Fiona and Sandy and the invaluable input they will provide us in developing our COVID-19 rapid response test,” he said.

“We are also pleased to report that our initial laboratory work is progressing well. As a result of our collaboration with GE, we expect to accelerate an aggressive pace in the development of this critical test,” Darren added.

Sona’s share price is down 12.05 per cent, and is currently trading at $0.73 per share, as of 11:05am EST.

More From The Market Herald

" The AI-driven cybersecurity platform that reached an overseas health care provider

Plurilock Security (TSXV:PLUR) received a sale order for ‘Plurilock AI’ with an overseas healthcare administrative services provider.

" WELL Health NCIB suggests undervaluation

WELL Health has entered into an automatic share purchase plan to facilitate share repurchases.
The Market Herald Video

" (C.NTAR) (NEXCF) Showcases Its Patent Pending Groundbreaking AI for Fixed Point Diffusion of 2D to 3D Model Conversion

The Market Herald Video

" (C.ARWY) (ARWYF) Announces Cross Platform Compatibility Across Magic Leap & Hololens As it Prepares For Additional AR Glasses Compatibility